Highlights Omeros Corporation

Equities

OMER

US6821431029

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
3.36 ^USD	+1.82%		-20.00%	+2.75%

May. 16	Health Care Flat as Momentum Wanes -- Health Care Roundup	DJ
May. 15	Transcript : Omeros Corporation, Q1 2024 Earnings Call, May 15, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Health Care Flat as Momentum Wanes -- Health Care Roundup	May. 16	DJ
Omeros Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024.	Apr. 01	CI
Omeros Corporation announces an Equity Buyback for $50 million worth of its shares.	Apr. 01	CI
Omeros Swings to Q4 Net Loss; Q1 Outlook Set	Apr. 01	MT
Omeros Corporation Provides Earnings Guidance for the First Quarter of 2024	Apr. 01	CI
Omeros Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Omeros Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance	Feb. 01	MT
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Omeros Corporation authorizes a Buyback Plan.	Nov. 08	CI
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting	Nov. 02	CI
Novartis drug candidate scores interim win in rare kidney disease trial	23-10-30	RE
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy	23-10-16	CI
Omeros Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Omeros Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria	23-04-25	CI
Omeros Receives $6.69 Million Grant From National Institute on Drug Abuse to Treat Cocaine Use Disorder	23-04-10	MT
Omeros Q4 Loss Narrows	23-03-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Omeros Corporation

Equities

OMER

US6821431029

Highlights

Filters